00:40 , Oct 19, 2018 |  BC Innovations  |  Emerging Company Profile

Altheia: Proliferating PD-L1

Rather than blocking PD-L1 to treat cancer, Altheia Science s.r.l. is increasing expression of PD-L1 via a cell therapy to promote immune tolerance in autoimmune diseases, starting with Type I diabetes and multiple sclerosis. Altheia...
21:19 , Oct 15, 2018 |  BC Extra  |  Preclinical News

mAb blocks fibrin's inflammation without clotting interference to treat MS, Alzheimer's

Gladstone Institutes researchers developed a mAb that could help treat neurodegenerative and autoimmune CNS diseases such as multiple sclerosis or Alzheimer's disease by specifically blocking the proinflammatory effects of fibrin without compromising its clotting ability....
17:34 , Oct 15, 2018 |  BC Extra  |  Company News

New CEO Forster eyes capital raise for F-star

Immuno-oncology company F-star Biotechnology Ltd. (Cambridge, U.K.) named Eliot Forster as CEO, replacing John Haurum. Forster was CEO of Oxford-based TCR biologics play Immunocore Ltd. (Abingdon, U.K.), which he left in February. Since becoming CEO...
18:10 , Oct 12, 2018 |  BC Week In Review  |  Clinical News

Phase II data for Merck's Btk inhibitor highlighted at ECTRIMS

Merck KGaA (Xetra:MRK) reported 24-week data from a Phase II trial to treat relapsing multiple sclerosis showing that evobrutinib (M2951) reduced the mean total number of gadolinium-enhancing T1 lesions by up to 2.7 over placebo....
17:34 , Oct 12, 2018 |  BC Week In Review  |  Clinical News

FDA, EMA to review Novartis' siponimod for secondary progressive MS

Novartis AG (NYSE:NVS; SIX:NOVN) said FDA and MAA have accepted applications for siponimod (BAF312) to treat secondary progressive multiple sclerosis (SPMS). The PDUFA date for the NDA is in March 2019; Novartis expects a decision...
12:15 , Oct 12, 2018 |  BC Extra  |  Clinical News

Phase II data for Merck's Btk inhibitor highlighted at ECTRIMS

Merck KGaA (Xetra:MRK) reported 24-week data from a Phase II trial to treat relapsing multiple sclerosis showing that evobrutinib (M2951) reduced the mean total number of gadolinium-enhancing T1 lesions by up to 2.7 over placebo....
19:21 , Oct 11, 2018 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease

INDICATION: Multiple sclerosis (MS) Mouse studies suggest PTPRS mimetics could help treat MS. In the experimental autoimmune encephalomyelitis (EAE) mouse model of MS, a small peptide mimetic of PTPRS decreased clinical disease scores, demyelinated spinal...
18:27 , Oct 8, 2018 |  BC Extra  |  Company News

FDA, EMA to review Novartis' siponimod for secondary progressive MS

Novartis AG (NYSE:NVS; SIX:NOVN) said FDA and MAA have accepted applications for siponimod (BAF312) to treat secondary progressive multiple sclerosis (SPMS). The PDUFA date for the NDA is in March 2019; Novartis expects a decision...
22:33 , Oct 4, 2018 |  BC Innovations  |  Tools & Techniques

No crisp upper hand in CRISPR

While the most recent ruling in the ongoing CRISPR IP battle maintained the Broad Institute’s dominant patent position in the U.S., University of California Berkeley’s dominant position in Europe, coupled with the looming possibility of...
16:34 , Sep 21, 2018 |  BC Week In Review  |  Company News

Servier declines rights to GeNeuro's GNbAC1

Servier (Neuilly-sur-Seine, France) declined to exercise an option to license rights outside the U.S. and Japan from GeNeuro S.A. (Euronext:GNRO) to develop and commercialize GNbAC1 to treat multiple sclerosis. The companies said Servier's decision was...